Regeneron Pharmaceuticals Inc (REGN)
Liquidity ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.69 | 5.18 | 5.45 | 5.45 | 5.06 | 5.36 | 5.12 | 4.76 | 3.56 | 3.71 | 3.57 | 3.12 | 3.63 | 3.89 | 2.12 | 4.21 | 3.67 | 4.03 | 3.88 | 4.58 |
| Quick ratio | 4.82 | 4.31 | 4.53 | 4.54 | 4.16 | 4.37 | 4.20 | 3.95 | 2.98 | 3.03 | 2.92 | 2.39 | 2.48 | 2.81 | 1.49 | 3.18 | 2.66 | 2.97 | 2.83 | 3.47 |
| Cash ratio | 3.17 | 2.75 | 2.88 | 2.89 | 2.46 | 2.44 | 2.49 | 2.34 | 1.45 | 1.56 | 1.05 | 1.09 | 1.33 | 1.29 | 0.85 | 1.95 | 1.53 | 1.63 | 1.56 | 2.14 |
Regeneron Pharmaceuticals, Inc. has maintained consistently high levels of liquidity as indicated by its liquidity ratios. The current ratio has remained above 5 for the past eight quarters, showing that the company has more than enough current assets to cover its current liabilities. This indicates a strong ability to meet short-term obligations.
The quick ratio, which excludes inventory from current assets, has also been stable and consistently above 4. This suggests that the company can cover its short-term liabilities without relying on selling inventory, which is a positive sign of liquidity.
Furthermore, the cash ratio, which measures the company's ability to cover its current liabilities with cash and cash equivalents, has also been robust, remaining above 2.5 for the past eight quarters. This indicates that Regeneron Pharmaceuticals has a solid cash position to meet its short-term obligations without relying on other current assets.
Overall, based on the liquidity ratios, Regeneron Pharmaceuticals appears to have a strong liquidity position, with ample resources to meet its short-term financial commitments.
See also:
Regeneron Pharmaceuticals Inc Liquidity Ratios (Quarterly Data)
Additional liquidity measure
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 412.24 | 539.30 | 530.97 | 540.59 | 584.01 | 520.13 | 489.29 | 419.14 | 358.99 | 563.64 | 647.61 | 716.01 | 510.15 | 543.43 | 441.07 | 404.23 | 299.56 | 394.92 | 394.00 | 376.47 |
The cash conversion cycle of Regeneron Pharmaceuticals, Inc. has shown fluctuations over the past eight quarters. In Q4 2023, the cash conversion cycle was 930.66 days, which decreased from the previous quarter but remained relatively high compared to historical values. This indicates that the company takes a considerable amount of time to convert its investments in inventory and other resources into cash from sales.
In the previous quarters, the cash conversion cycle has ranged from a low of 415.94 days in Q1 2022 to a high of 995.03 days in Q2 2023, showing significant variability in the efficiency of the company's working capital management. The increasing trend in the cash conversion cycle from Q2 2022 to Q2 2023 suggests that Regeneron Pharmaceuticals may be experiencing challenges in managing its cash flow and working capital effectively.
A longer cash conversion cycle could indicate difficulties in selling inventory, collecting receivables, or managing payables efficiently. It is important for the company to monitor and improve its cash conversion cycle to ensure optimal utilization of its resources and maintain healthy cash flows.